92 related articles for article (PubMed ID: 33199495)
1.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
2.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction.
Ge Q; Zhao Z; Li X; Yang F; Zhang M; Hao Z; Liang C; Meng J
Clin Transl Med; 2024 Jan; 14(1):e1552. PubMed ID: 38239097
[No Abstract] [Full Text] [Related]
4. Large tandem duplications in cancer result from transcription and DNA replication collisions.
Yang Y; Badura ML; O'Leary PC; Delavan HM; Robinson TM; Egusa EA; Zhong X; Swinderman JT; Li H; Zhang M; Kim M; Ashworth A; Feng FY; Chou J; Yang L
medRxiv; 2024 Jan; ():. PubMed ID: 38260434
[TBL] [Abstract][Full Text] [Related]
5. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
6.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
7. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
[TBL] [Abstract][Full Text] [Related]
8. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
9. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
[TBL] [Abstract][Full Text] [Related]
10. ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
Rao AA; Madejska AA; Pfeil J; Paten B; Salama SR; Haussler D
Front Immunol; 2020; 11():483296. PubMed ID: 33244314
[TBL] [Abstract][Full Text] [Related]
11. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers.
Rubin MA; Bristow RG; Thienger PD; Dive C; Imielinski M
Mol Cell; 2020 Nov; 80(4):562-577. PubMed ID: 33217316
[TBL] [Abstract][Full Text] [Related]
12. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Yi J; Zhu J; Wu J; Thompson CB; Jiang X
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31189-31197. PubMed ID: 33229547
[TBL] [Abstract][Full Text] [Related]
14. Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
de Wit R; Tombal B; Freedland S
Eur Urol; 2021 Feb; 79(2):170-172. PubMed ID: 33218827
[TBL] [Abstract][Full Text] [Related]
15. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
[TBL] [Abstract][Full Text] [Related]
16. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
17. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
[TBL] [Abstract][Full Text] [Related]
18. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
19. First Experiences with
Prasad V; Zengerling F; Steinacker JP; Bolenz C; Beer M; Wiegel T; Eiber M; Fleshner N; Beer AJ
J Nucl Med; 2021 Jul; 62(7):975-978. PubMed ID: 33246977
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
